Wire · opportunities
Cleveland Clinic-led trial finds drug lowered lipoprotein(a), but did not reduce major heart events
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 November 2026 · Fusion42 review
A Cleveland Clinic-led Phase 3 trial found that the drug pelacarsen lowered lipoprotein(a) by 78.4% but did not reduce major cardiovascular events compared to placebo over nearly five years. The trial involved 8,322 patients globally with high Lp(a) and existing cardiovascular disease, indicating that lowering Lp(a) alone may not reduce heart attacks or strokes.
This Wire brief sits within Fusion42's coverage of Biotech, Drug Discovery and Medtech, and 4 sources have reported it between 7 Nov 2026 and 8 Nov 2026.
◆ ◆ The Wire takeaway
Your work targeting lipoprotein(a) for heart risk must now justify beyond biomarker reduction as pelacarsen’s trial showed no event improvement. You need new strategies or markers to prove clinical benefit or explore alternative patient groups and emerging gene-silencing approaches.
◆ Coverage
4 sources · first reported 7 Nov 2026 · latest 8 Nov 2026
◆ Related on Wire
◆ Topics